[1] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)［J］. 中华神经科杂志, 2014, 47(6):428-433.
[2] 王惠霞,武新安,何忠芳. 帕金森病一例药学监护实践［J］. 临床合理用药杂志, 2012,12(5): 85-86.
[3] Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines［S］. Neurology, 2001,56(11): S1-S88.
[4] 刘春风,尹伟华,罗蔚锋.帕金森病患者运动障碍和症状波动的影响因素［J］.中华神经科杂志,2003, 36(6): 411-413.
[5] Zhang ZX, Chen H, Chen SD, et al.Chinese culture permeation in the treatment of Parkinson disease:a cross-sectional study in four regions of China［J］. BMC Res Notes, 2014, 7: 65.
[6] Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease［J］. Mov Disord, 2013, 28(8):1064-1071.
[7] 中华医学会神经病学分会神经心理学与行为神经病学组, 中华医学会神经病学分会神经心理学与行为神经病学组. 帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南［J］.中华神经科杂志,2013,46(1):56-60.
[8] 江开达.中华医学会精神科分会.抑郁障碍防治指南［M］.北京:北京大学医学出版社,2007:21.
[9] Barone P,Poewe W,Albrecht S,et al.Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease:a randomised,double-blind,Placebo-controlled trial［J］.Lancet Neurol,2010,9(6):573-580.
[10] O'Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study［J］. Mov Disord, 2008, 23(1): 101-106.
[11] Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms［J］. Mov Disord, 2014, 29(2):195-202.
[12] Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study［J］. Mov Disord, 2000,15(4): 669-677.
[13] Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study［J］. Mov Disord, 2003,18(4): 414-418.
[14] Gonera EG, van't Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson's disease［J］. Mov Disord, 1997,12(6): 871-876.
[15] Shen CC,Tsai SJ, Perng CL, et al. Risk of Parkinson disease after depression: a nationwide population-based study［J］. Neurology,2013, 81(17): 1538-1544.
[16] Breier A, Sutton V, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease［J］. Biol Psychiatry,2002, 52(5): 438-445.
[17] Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatnlent for dopaminergic-induced hallucinations［J］. Mov Disord, 2002, 17(5):1031-1035.
[18] Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine:comparative effects on motor function in hallucinating PD patients［J］. Neurology,2000, 55(6): 789-794.
[19] Friedman JH. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease［J］. Neuorlogy,1998, 50(4):1195-1196.
[20] Seppi K, Weintraub D, Coelho M, et a1. The movement disorder society evidence-based medicine review update:treatments for the non-motor symptoms of Parkinson's disease［J］. Mov Disord,2011, 26(3): S42-80.